Details

Titel

Livzon Pharmaceutical Group 1 September 2021 – Sep 1, 2021

Ist Teil von

• Company SnapShot, 2021

Ort / Verlag

Yass: Acquisdata Pty Ltd

Erscheinungsjahr

2021

Beschreibungen/Notizen

• LATEST FINANCIAL ANNOUNCEMENT Livzon Pharmaceutical Group (SHE: 00513) Q2 2021 1 September 2021 Associate: Audrey Awie 2021 Interim Report For the full release, see: https://www.livzon.com.cn/public/html/pdfjs/viewer/viewernew.html?file=https://v4.cecdn.yun300.cn/site_1809140982/c101_ess1630492010636.pdf # Acquisdata is proud to be hosting a league on Estimize. Want the opportunity to win free subscriptions? Then join the Acquisdata Media and Telecommunications League at: https://www.estimize.com/leagues/acquisdata-media-and-telecommunications # https://www.facebook.com/acquisdata/ https://twitter.com/acquisdata COMPANY PROFILE Livzon Pharmaceutical Group (SHE: 000513) Livzon Pharmaceutical Group Inc. is a comprehensive pharmaceutical enterprise integrating research & development (R&D), production and marketing of medical and pharmaceutical products. It was founded with a registered capital of RMB 719 million in January 1985. By 2018, the total assets of the company were over RMB 17 billion, and the annual turnover was RMB 8.86 billion with more than RMB 1 billion net profit attributable to the shareholders of the Company. The Livzon Pharmaceutical Group has invested approximately RMB 687 million in R&D. In 1993, the stock of the Livzon Pharmaceutical Group was listed on the A-share, and subsequently the B-share market. In 2014, Livzon Pharmaceutical Group stock was successfully transferred from B-share to ...